Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators

Journal of Medicinal Chemistry

Volumn 50, Issue 16, 2007, Pages 3857-3869

  Zhang, Xuqing ^a   Li, Xiaojie ^a   Allan, George F ^a   Sbriscia, Tifanie ^a   Linton, Olivia ^a   Lundeen, Scott G ^a   Sui, Zhihua ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL 5 TRIFLUOROMETHYL 3,4 DIHYDRO 2H PYRAZOLE 3 CARBOXYLIC ACID (4 CYANO 3 TRIFLUOROMETHYLPHENYL)AMIDE; ANABOLIC AGENT; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; PYRAZOLINE DERIVATIVE; TESTOSTERONE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CASTRATION; CONTROLLED STUDY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; IN VIVO STUDY; ISOMER; MALE; MUSCLE TISSUE; NONHUMAN; PROSTATE; RAT; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION;

ANABOLIC AGENTS; ANILIDES; ANIMALS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; MALE; MOLECULAR STRUCTURE; MUSCLE, SKELETAL; ORCHIECTOMY; ORGAN SIZE; PELVIC FLOOR; PROSTATE; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE;

EID: 34548062694     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0613976     Document Type: Article

References (45)

1. Liu, P. Y.; Swerdloff, R. S.; Veldhuis, J. D. The rationale, efficacy and safety of androgen therapy in older men: Future research and current practice recommendations. J. Clin. Endocrinol. Metab. 2004, 89, 4789-4796.
2. (a) Chengalvala, M.; Oh, T.; Roy, A. K. Selective androgen receptor modulators. Expert Opin. Ther. Pat. 2003, 13, 59-66.
3. (b) Gao, W.; Bohl, C. E.; Dalton, J. T. Chem. Rev. Chemistry and structural biology of androgen receptor. 2005, 105, 3352-3370.
4. (c) Chen, J.; Kim, J.; Dalton, J. T. Discovery and therapeutic promise selective androgen receptor modulators. Mol. Interventions 2005, 5, 173-188.
5. (d) Basaria, S.; Wahlstrom, J. T.; Dobs, A. S. Clinical review 138: Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J. Clin. Endocrinol. Metab. 2001, 86, 5108-5117.
6. (e) Shahidi, N. T. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin. Ther. 2001, 23, 1355-1390.
7. Allan, G.; Sui, Z. Selective Androgen Receptor Modulators. NURSA e-Journal 2003, 1, e009, 7 pp. 〈http://www.nursa.org/ article.cfm〉 (doi 10.1621/nrs.01009).
8. Bhasin, S.; Bremner, W. J. Clinical review 85: emerging issues in androgen replacement therapy. Clin. Endocrinol. Metab. 1997, 82, 3-8.
9. (a) Labrie, F. Mechanism of action and pure antiandrogenic properties of flutamide. Cancer 1993, 72, 3816-27.
10. (b) Furr, B. J.; Valcaccia, B.; Curry, B.; Woodburn, J. R.; Chesterson, G.; Tucker, H. ICI 176,-334: a novel non-steroidal, peripherally selective antiandrogen. J. Endocrinol. 1987, 113, R7-9.
11. (c) Furr, B.J. The development of Casodex (bicalutamide): preclinical studies. Eur. Urol. 1996, 29 (Suppl. 2), 83-95.
12. (d) Kolvenbag, G. J.; Blackledge, G. R. Worldwide activity and safety of bicalutamide: a summary review. Urology 1996, 47 (Suppl. 1A), 70-79.
13. (e) Dole, E. J.; Holdsworth, M. T. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann. Pharmacother. 1997, 31, 65-75.
14. (a) Cosman, F.; Lindsay, R. Selective estrogen receptor modulators: clinical spectrum. Endocr. Rev. 1999, 20, 418-434.
15. (g) Katzenellenbogen, J. A.; O'Malley, B. W.; Katzenellenbogen, B. S. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 1996, 10, 119-131.
16. (c) McDonnell, D. P.; Clemm, D. L.; Hermann, T.; Goldman, M. E.; Pike, J. W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 1995, 9, 659-669.
17. (d) Baracat, E.; Haidar, M.; Lopez, F. J. Pickar J; Dey, M.; Negro-Vilar, A. Estrogen activity and novel tissue selectivity of delta 8,9-dehydroestrone sulfate in postmenopausal women. J. Clin. Endocrinol. Metab. 1999, 84, 2020-2027.
18. (a) Negro-Vilar, A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J. Clin. Endocrinol. Metab. 1999, 84, 3459-62.
19. (b) Zhi, L.; Martinborough, E. Selective androgen receptor modulators (SARMs). Ann. Rep. Med. Chem. 2001, 36, 169-180.
20. Lee, Y. F.; Shyr, C. R.; Thin, T. H.; Lin, W. J.; Chang, C. Convergence of two repressors through heterodimer formation of androgen receptor and testicular orphan receptor-4: a unique signaling pathway in the steroid receptor superfamily. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 14724-9.
21. (a) Gronemeyer, H.; Gustafsson, J. A.; Laudet, V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 2004, 3, 950-954.
22. (b) Mooradian, A. D.; Morley, J. E.; Korenman, S. G. Biological actions of androgens. Endocr. Rev. 1987, 8, 1-28.
23. Dalton, J. T.; Mukherjee, A.; Zhu, Z.; Kirkovsky, L.; Miller, D. D. Discovery of nonsteroidal androgens. Biochem. Biophys. Res. Commun. 1998, 244, 1-4.
24. Hamann, L.G. Discovery and preclinical profile of a highly potent and muscle selective androgen receptor modulator (SARM). Natl. Meet. Am. Chem. Soc., Med. Chem. Div. 2004, 227, MEDI-011.
25. (a) Hamann, L. G.; Mani, N. S.; Davis, R. L.; Wang, X.-N.; Marschke, K. B.; Jones, T. K. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6- g]-quinoline (LG121071). J. Med. Chem. 1999, 42, 210-212.
26. (b) Edwards, J. P.; Higuchi, R. I.; Winn, D. T.; Pooley, C. L. F.; Caferro, T. R.; Marschke, K. B.; Hamann, L. G.; Zhi, L.; Jones, T. K. Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H- pyrano[3,2-g]quinolin-2-one. Bioorg. Med. Chem. Lett. 1999, 9, 1003-08.
27. (c) Van Oeveren, A.; Motamedi, M.; Mani, N. S.; Marschke, K. B.; Lopez, F. J.; Schrader, W. T.; Negro-Vilar, A.; Zhi, L. Discovery of 6-N,N-Bis(2,2,2-trifluoroethyl)amino-4-trifluoromethylquinolin-2(1 H)-one as a Novel Selective Androgen Receptor Modulator. J. Med. Chem. 2006, 49, 6143-46.
28. Miyakawa, M.; Oguro, N.; Hanada, K.; Furuya, K.; Yamanoto, N. Preparation of novel tetrahydroquinoline derivatives as androgen receptor agonists. PCT Int. Appl. WO 2004013104, 2004.
29. Segal, S.; Narayana, R.; Dalton, J. T. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin. Invest. Drugs 2006, 15, 377-387.
30. Zhang, X.; Li, X.; Allan, G. F.; Sbriscia, T.; Linton, O.; Lundeen, S. G.; Sui, Z. Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgen receptor modulators. Bioorg. Med. Chem. Lett. 2007, 17, 439-443.
31. (a) Marhefka, C. A.; Gao, W.; Chung, K.; Kim, J.; He, Y.; Yin, D.; Bohl, C.; Dalton, J. T.; Miller, D. D. Design synthesis, and biol. characterization of metabolically stable selective androgen receptor modulators. J. Med. Chem. 2004, 47, 993-998.
32. (b) Zhang, X.; Li, X.; Allan, G.; Musto, A.; Lundeen, S. G.; Sui, Z. Discovery of indolecontaining tetracycles as a new scaffold for androgen receptor ligands. Bioorg. Med. Chem. Lett. 2006, 16, 3233-3237.
33. (c) Zhang, X.; Li, X.; Allan, G. F.; Sbriscia, T.; Linton, O.; Lundeen, S. G.; Sui, Z. Synthesis and SAR of novel hydantoin derivatives as selective androgen receptor modulators. Bioorg. Med. Chem. Lett. 2006, 16, 5763-5766.
34. (d) Lanter, J. C.; Fiordeliso, J. J.; Allan, G. F.; Musto, A.; Hahn, D.; Sui, Z. A bioisosteric approach to the discovery of indole carbinol androgen receptor ligands. Bioorg. Med. Chem. Lett. 2006, 16, 5646-5649.
35. (e) Lanter, J.; Fiordeliso, J. J.; Jiang, W.; Allan, G. F.; Lai, M.; Hahn, D.; Lundeen, S. G.; Sui, Z. The discovery of a potent orally efficacious indole androgen receptor antagonist through in vivo screening. Bioorg. Med. Chem. Lett. 2007, 17, 123-126.
36. (f) Ng, R. A.; Guan, J.; Alford, V. C., Jr.; Lanter, J.; Allan, G.; Sbriscia, T.; Linton, O.; Lundeen, S.; Sui, Z. Synthesis and SAR of potent and selective androgen receptor antagonists: 5,6-dichlorobenzimidazole derivatives. Bioorg. Med. Chem Lett. 2007, 17, 955-958.
37. Herschberger, L. G.; Shipley, E. G.; Meyer, R. K. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc. Soc. Exp. Biol. Med. 1953, 83, 175-80.
38. (a) Varney, M. D.; Palmer, C. L.; Deal, J. G.; Webber, S.; Welsh, K. M.; Bartlett, C. A.; Morse, C. A.; Smith, W. W.; Janson, C. A. Synthesis and biological evaluation of novel 2,6-diaminobenz[cd]-indole inhibitors of thymidylate synthase using the protein structure as a guide. J. Med. Chem. 1995, 38, 1892-1893.
39. (b) Kirkovsky, L.; Mukherjee, A.; Yin, D.; Dalton, J. T.; Miller, D. D. Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring. J. Med. Chem. 2000, 43, 581-590.
40. (c) Mukherjee, A.; Kirkovsky, L.; Yao, X. T.; Yates, R. C.; Miller, D. D. Enantioselective binding of Casodex to the androgen receptor. Xenobiotica 1996, 26, 117-122.
41. For Cos-7 whole cell binding assay, see: Hammann, L. G.; Higuchi, R. I.; Zhi, L.; Edwards, J. D.; Wang, X.-N.; Marsckle, K.; Kong, J. W.; Farmer, L. J.; Jones, T. K. Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. J. Med. Chem. 1998, 41, 623-639.
42. For LNCap assay, see: Salvati, M. E.; Balog, A.; Pickering, D. A.; Giese, S.; Fura, A.; Li, W.; Patel, R.; Hanson, R. L.; Mitt, T.; Roberge, J.; Corte, J. R.; Spergel, S. H.; Rampulla, R. A.; Misra, R.; Xiao, H.-Y. Preparation of fused succinimides as modulators of nuclear hormone receptor function. PCT Int. Appl. WO 2003062241, 2003.
43. Allan, G. F.; Tannenbaum, P.; Sbriscia, T.; Linton, O.; Lai, M.-T.; Haynes-Johnson, D.; Bhattacharjee, S.; Zhang, X.; Sui, Z.; Lundeen, S. G. A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats. Endocrinology, submitted.
44. Chen, B.-C.; Sundeen, J. E.; Zhao, R. Process for the preparation of N-(substituted phenyl)-3-alkyl-, aryl- and heteroarylsulfonyl-2-hydroxy- 2-alkyl- and haloalkylpropanamide antiandrogenic compounds. PCT Int. Appl. WO 2002024638, 2002.
45. Tucker, H.; Crook, J. W.; Chesterson, G. J. Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. J. Med. Chem. 1988, 31, 954-9.